New class of antigen-specific cancer immunotherapy
based on an off-the-shelf antigen presenting cell line

News

PDC*line Pharma raises €20 million ($22.2M) in Series B financing round

2020-01

Liège, Belgium and Grenoble, France, January 22, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today the completion of its Series B round of

Read more about PDC*line Pharma raises €20 million ($22.2M) in Series B financing round

The PDC*line Pharma management team will be present in full force in San Francisco during the JP Morgan Conference 2020

2020-01

The PDC*line Pharma management team will be present in full force in San Francisco during the JP Morgan Conference 2020! Meet our President & CEO Eric Halioua and our COO Laurent Levy from Sunday Jan.12th to Thursday Jan.16th ! #lungcancer #oncology

Read more about The PDC*line Pharma management team will be present in full force in San Francisco during the JP Morgan Conference 2020

A new article published l'echos underlining the achievements made by PDC*line Pharma over the last 4 years.

2019-12

Today, a new article has been published in the newspaper l'Echos with an interview of our President & CEO Eric Halioua .The article underlines the achievements made by PDC*line Pharma over the last 4 years. Have a look at the article by clicking the

Read more about A new article published l'echos underlining the achievements made by PDC*line Pharma over the last 4 years.

PDC*line Pharma is hiring! We have an open position for a Senior/Principal Scientist.

2019-12

PDC*line Pharma is hiring! We have an open position for a Senior/Principal Scientist. Are you interested to join an international dynamic team in the biotech cancer vaccine space? Be part of the adventure and join us!

In order to strengthen the team

Read more about PDC*line Pharma is hiring! We have an open position for a Senior/Principal Scientist.

Our President & CEO will make a company presentation at the Belgium-Korea Pharma-Bio Partnering on the 13th November 2019

2019-11

Our President & CEO Eric Halioua will make a company presentation at the Belgium-Korea Pharma-Bio Partnering on the 13th November 2019 in Brussels. This seminar organized by Korea Trade-Investment Promotion Agency in Brussels KOTRA will provide an

Read more about Our President & CEO will make a company presentation at the Belgium-Korea Pharma-Bio Partnering on the 13th November 2019

linkedin twitter

PDC*line Pharma

Founded in April 2014 in Grenoble (France) as a spin-off of the French Blood Bank (Etablissement Français du Sang, EFS), PDC*line Pharma is a Belgian-French biotech company that is developing a novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) pre-loaded with peptides that are derived from target tumor antigens. Based on a robust preclinical package and a first-in-human phase Ib feasibility study in melanoma, PDC*line Pharma is focusing on lung cancer with a new candidate in early clinical development (PDC*lung) and on neoantigens (PDC*Neo). PDC*line Pharma comprises a team of highly skilled professionals based in Liège (Belgium) and Grenoble (France).

About us

A first in class Plasmacytoid Dendritic cell line, PDC*line providing unmatched advantages

Potent & effective

Induction of a strong cytotoxic immune response directed against a selection of tumour antigens

Scalable & convenient

Simple production of a large quantity of a highly qualified off-the-shelf product

Versatile & applicable to any cancers

The peptides can easily be changed to target a specific cancer type

Management Team

Candidate products

Melanoma

Melanoma is the most lethal form of skin cancer, representing 2% of all newly diagnosed cancer cases (232,000 new cases and 55,000 deaths worldwide in 2012). It is also the leading cancer in terms of incidence increase (+ 10% per year) and one of the most common cancers in young adults (18-35 years).

Melanoma is often easier to detect in its early stages than most cancers. However, it is also more likely to spread (metastasize) to other parts of the body, and 16% of patients are first diagnosed at an advanced stage. Despite new treatments, prognosis for this late-stage disease is very unfavorable (5-year mortality rate of 85%).

Read more about PDC mel

Lung Cancer

Lung cancer is the most common malignancy worldwide for male patients and for both sexes combined (2.1 million new cases per year), and the third most common for female patients (after breast and colorectal cancers). Deaths from lung cancer exceed those from any other malignancy globally, with the number of lung-cancer-related deaths worldwide for 2018 estimated at 1.8 million (Globocan 2018), representing 18.4% for both sexes. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, representing 80% of cases.

Read more about Lung Cancer

Technology

PDC*line, our proprietary allogeneic cell line of Plasmacytoid Dendritic Cells solves the industrial limitations faced by immunotherapies based on dendritic cells currently on the market or in clinical development. Additionally PDC*line is much more potent than conventional dendritic cells to expand anti-tumor CD8+ T cells in vitro.

About our technology